<?xml version="1.0" encoding="UTF-8"?>
<p>A limitation of this study was the predominance of male patients, with females representing only 29% of the study population. Gender is a well-established risk factor, with females at greater risk for CINV. In two recent identically designed rolapitant trials, the difference in proportions of males/females in the studies was deemed as a potential factor that may have contributed to differing antiemetic efficacy in the studies [
 <xref rid="mdx698-B22" ref-type="bibr">22</xref>]. As gender was balanced for the NEPA and APR/GRAN groups within this study, this should not have influenced these results.
</p>
